First Tracks Biotherapeutics, Inc. Form 8-K — Oct 20, 2026
First Tracks Biotherapeutics closed a private placement on October 19, 2026, issuing 6,106,870 shares of common stock to private investors. No purchase price per share or gross proceeds are disclosed in the 8-K, but the share count represents meaningful dilution for this Nasdaq-listed emerging growth biotech. Concurrent with closing, the company signed a registration rights agreement requiring it to file a resale registration statement covering the new shares within 30 days and to keep it effective. If the company misses filing or effectiveness deadlines, it owes investors liquidated damages of 1.0% of their purchase amount per 30-day period, capped at 5.0% per investor.
Key figures
- Shares Offered
- 6106870
- Effectiveness deadline
- earlier of 60 days after filing (if reviewed) or 5 business days after no-review notice
- Liquidated damages cap
- 5.0% of aggregate purchase price per Investor
- Liquidated damages rate
- 1.0% of aggregate purchase amount per 30-day period
- Registration filing deadline
- 30 days after Closing Date
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.